about
Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applicationsStability engineering of the human antibody repertoireImproving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsBoosting antibody developability through rational sequence optimization.Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesisIn silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive TumorsStructural Determinants of Unique Properties of Human IgG4-FcN-terminal β-strand swapping in a consensus-derived alternative scaffold driven by stabilizing hydrophobic interactionsStructure-based prediction of asparagine and aspartate degradation sites in antibody variable regionsEndoglucanases: insights into thermostability for biofuel applicationsAdvances in Antibody DesignOn the role of aggregation prone regions in protein evolution, stability, and enzymatic catalysis: insights from diverse analyses.Protein aggregation and lyophilization: Protein structural descriptors as predictors of aggregation propensity.Wetting of nonconserved residue-backbones: A feature indicative of aggregation associated regions of proteins.CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.Predictive approach for protein aggregation: Correlation of protein surface characteristics and conformational flexibility to protein aggregation propensity.A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations.Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange.High-throughput analysis of concentration-dependent antibody self-association.Data on correlation between Aβ42 structural aggregation propensity and toxicity in bacteria.Understanding the interaction determinants of CAPN1 inhibition by CAST4 from bovines using molecular modeling techniques.Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation.Protein thermostability calculations using alchemical free energy simulationsStructural characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase protofibrils preventing α-synuclein oligomeric species toxicityComputational study of aggregation mechanism in human lysozyme[D67H]Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody.Therapeutic protein aggregation: mechanisms, design, and control.PROTS-RF: a robust model for predicting mutation-induced protein stability changes.Comparative analysis of human γD-crystallin aggregation under physiological and low pH conditions.Structure based descriptors for the estimation of colloidal interactions and protein aggregation propensitiesIn silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.Isolation and optimization for affinity and biophysical characteristics of anti-CCL17 antibodies from the VH1-69 germline gene.Antibody engineering for increased potency, breadth and half-life.Thermal stabilization of dihydrofolate reductase using monte carlo unfolding simulations and its functional consequences.Chaperone-like effect of the linker on the isolated C-terminal domain of rabbit muscle creatine kinase.Nanoyeast and Other Cell Envelope Compositions for Protein Studies and Biosensor Applications.Ultrahigh-throughput-directed enzyme evolution by absorbance-activated droplet sorting (AADS).Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs.Computer-aided antibody design.
P2860
Q26824543-9115FB9B-7A1E-401C-972C-D7A67D148B4AQ26859495-1C66BD70-6A5D-4810-9585-D01BF54D0A11Q27002558-D0FAB417-0952-427B-B077-18A74135D150Q27311159-054169CC-1029-4D82-B51D-E84B6D0328ABQ27660092-626964A5-CF9A-4812-B9E6-C4EFCF71C3ABQ27678257-FAA94F5D-7DA9-40A0-95B9-75F89456AEC5Q27680566-BC7B4EDD-DD6B-4290-80B0-65375D30D88BQ27688980-9A1E0CDD-9DE9-4CE7-BF5A-F755B4FFD380Q28539968-506B26D8-97EF-4048-9BAC-2EE50FCD8E08Q28661239-DCE65D65-D4A8-4B89-8F2F-FC9B4E8794DAQ28817608-E68AC689-62B2-491A-A91D-BC1A40207C8EQ30354782-5EFAD778-100B-4B98-8358-0066881AD8B9Q30358865-5CF505AF-1B40-49CF-B4F4-8D1BF0446D56Q30382591-A8B80CD7-0D54-4FA5-93E1-5C6A8C6BA047Q30383481-DA08F22E-A5D6-4D6E-BB00-17B858522F98Q30384220-7FB34731-88FE-4161-B446-BAD24A436C27Q30391417-1FF78FF8-C7A5-4323-86EB-E82AA9C06EE8Q30422151-A87DDB68-124E-4E2A-9D18-BDFA109DCDE3Q30454017-E497A323-ABC0-4947-8ED8-FD7CC14E8A7BQ30462680-F0B07F2A-4C28-4344-852F-40B89FD7A8B1Q31114259-5D12C168-C3B5-4972-B658-E32B1D4C4507Q33359090-845F7486-00AE-426B-8AC5-788EA3BC5354Q33520919-6F13B0DB-43B3-4373-BFD9-2DD6DAC422D9Q33581606-82371D16-6AF0-4516-80FE-F346F9B7D9BFQ33619357-A76D6EB4-32B6-4DF8-80B7-433A055B2129Q33632612-CF3FB90A-49B3-428A-BE9D-89C999FAAC5CQ33648617-E023DA0E-8395-4857-AD7E-1CAD508BFCECQ34097620-7E1F1471-5F2B-4D2D-8668-40A92263A389Q34450654-BA2C05A5-C6F6-401D-8062-D5386E846AEAQ34497712-76E1297A-CFE1-43F1-9623-C11804737F17Q34658019-660A3DE1-6D7A-4AD7-A8E7-B1FE18468061Q34831383-6FD51011-697D-4E90-BFD3-46D35287B80FQ35151385-854DDA59-70FE-4AE5-8406-2D84FE325CF6Q35575206-92CDFFB6-9F04-4F0A-BF15-7613B0184391Q35612683-21E7B025-EB8E-462E-987D-35F34A76E9C5Q36150739-CB139602-8BB8-43C5-892E-381A15AEFFDAQ36168796-2401B898-5AE4-46BA-9224-8498ADDE46E5Q36185038-D43EFBF7-3113-44D8-98E4-C5EA35AC2178Q36213460-5207D251-3B9A-4DAC-9B6C-35F293EC098AQ36254449-2D78E5B3-C9FF-4830-938A-7677491909AD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design of therapeutic proteins with enhanced stability.
@en
Design of therapeutic proteins with enhanced stability.
@nl
type
label
Design of therapeutic proteins with enhanced stability.
@en
Design of therapeutic proteins with enhanced stability.
@nl
prefLabel
Design of therapeutic proteins with enhanced stability.
@en
Design of therapeutic proteins with enhanced stability.
@nl
P2093
P2860
P356
P1476
Design of therapeutic proteins with enhanced stability
@en
P2093
Bernhard Helk
Bernhardt L Trout
Naresh Chennamsetty
Vladimir Voynov
P2860
P304
11937-11942
P356
10.1073/PNAS.0904191106
P407
P577
2009-07-01T00:00:00Z